Treatment Strategy for Non-Responders to PDE5 Inhibitors.
10.5534/wjmh.2013.31.1.31
- Author:
Nam Cheol PARK
1
;
Tae Nam KIM
;
Hyun Jun PARK
Author Information
1. Department of Urology, Pusan National University School of Medicine, Busan, Korea. joon501@naver.com
- Publication Type:Review
- Keywords:
Erectile dysfunction;
Phosphodiesterase type 5 inhibitors;
Sildenafil;
Tadalafil;
Vardenafil
- MeSH:
Carbolines;
Erectile Dysfunction;
Humans;
Imidazoles;
Male;
Performance Anxiety;
Phosphodiesterase 5 Inhibitors;
Piperazines;
Purines;
Sulfones;
Treatment Failure;
Triazines;
Sildenafil Citrate;
Tadalafil;
Vardenafil Dihydrochloride
- From:The World Journal of Men's Health
2013;31(1):31-35
- CountryRepublic of Korea
- Language:English
-
Abstract:
Currently, phosphodiesterase type 5 (PDE5) inhibitors are the initial treatment option for erectile dysfunction. The reported efficacy of PDE5 inhibitors is about 70%, although it is significantly lower in difficult-to-treat subpopulations. Treatment failures might be due to the severity of the underlying pathophysiology, improper use of medication, unrealistic patient expectations, difficult relationship dynamics, severe performance anxiety, and other psychological problems. Physicians must address these issues to identify true treatment failures attributable to the drugs. This article discusses factors that might affect the response to PDE5 inhibitors and develops a strategy to maximize the overall efficacy of PDE5 inhibitors in initial non-responders to PDE5 inhibitors.
